Rhodia provides process and handling updates

By Kirsty Barnes

- Last updated on GMT

Related tags: Rhodia, Better

Rhodia was present at this year's CPhI, alerting the industry to
its latest product updates, spawned out of the market demand to
provide products that allow its customers to better address process
and handling requirements.

The global chemicals company said that it had made two new developments on its paracetamol and granular salycilic grades through "significant improvement of their physical properties."

RHODAPAP DC90, part of its direct compressible line of paracetamol and manufactured in its Chinese plant, now has the ability to compress without the need for pre-compression, as well as better hardness and lower friability, said the firm.

Rhodia also said that improvements to its granular salicylic acid grade now allow it to offer "enhanced flowability, reduced dusting, improved product handling and safety, reduction of foaming during mixing and reduced cross contamination."

This salycilic acid, manufactured at the company's Brazillian plant, "offers remarkable benefits compared to other commercially available brands on the market,"​ the company said.

Rhodia also announced the implementation of a new process technology in its UK plant for the manufacture of 1,1-biphosphonate drugs, which are commonly used to treat bone disorders.

"The process is faster and more selective, enabling more reliable and cost-effective batch production,"​ Ranbir Padda, research and development manager of Rhodia told In-PharmaTechnologist.com.

"The manufacture of phosphines is potentially hazardous and this new process also provides greater customer safety."

The new technology is applicable to the manufacture of materials such as alendronate, risedronate and zoledronate.

"Phosphorus chemistry is our specialty and we offer our customers joint development expertise and the possibility to outsource all their specialist phosphorus chemistry needs and so we will continue to develop new phosphorus based solutions at both commercial and lab scale quantities,"​ said Rhodia spokesperson Mike Harrision.

Rhodia said it has also developed a new process technology that has allowed it to introduce a new phosphine ligand to its product portfolio - tetra-t-butyldiphosphinoxylene (TBDPX) - a ligand typically used in carbonylation reactions.

"This ligand has many potential applications in pharmaceutical synthesis,"​ said the firm.

Related news

Show more

Related products

show more

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Related suppliers

Follow us


View more